Patient P-03225
Therapy response
Stable
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
56%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S19
- Day 102 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 102 GI-04 recommended — GI Support Protocol GI-04
- Day 103 Patient accepted — Started GI-04 in the companion
- Day 111 GI symptom burden −29% vs expected — GI Support Protocol GI-04
- Day 117 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 102.
Primary contributors, last 14 days
- Treatment adherence-12
- Toxicity+9
- GI instability+5
- Inflammatory activity+3
What helped?
- GI Support Protocol GI-04Day 102Result: symptom burden −29%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
66%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 80% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log2.6/10
stable · -0.1 vs previous 14 d
Stress level
Daily log5.7/10
improving · -0.2 vs previous 14 d
Pessimism score
Daily log4.7/10
improving · -0.3 vs previous 14 d
Sleep quality
Wearable15.9/100
worsening · -5.1 vs previous 14 d
Libido
Daily log3/10
worsening · -0.2 vs previous 14 d
HRV
Wearable38.9 ms
stable · +1.0 vs previous 14 d
Toxicity
Blood44.9/100
worsening · +7.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 33 from the failing basin, 56 from restoration.
Would help
- ME-01 Monitoring Escalation100% improved among 11 similar · onset 3 d · confidence 67%
- SC-12 Supportive Compound89% improved among 9 similar · onset 6 d · confidence 67%
- DT-01 Dosing / Timing Recommendation80% improved among 10 similar · onset 5 d · confidence 67%
- More proteinGI -3.6 next day on high-intake days · n 15
Would not help
- AD-05 Adherence Supportonly 30% improved among 10 similar
- Keep histamine lowGI +3.8 next day on high-intake days · n 22
- Keep caffeine lowGI +2.9 next day on high-intake days · n 23
- Keep lactose lowGI +2.7 next day on high-intake days · n 18
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+3.8detractor · 95%
- Protein-3.6supporter · 95%
- Caffeine+2.9detractor · 95%
- Lactose+2.7detractor · 95%
- Dietary fat load+2.4detractor · 88%
- Alcohol+0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 55 and rising
- WearableSleep 5.2 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 45
- Autonomic recovery ↓45
- WearableResting HR 80 bpm
- WearableShort sleep window
- Inflammatory signalling ↑25
- BloodInflammatory load index 54
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.6 · butyrate capacity 38/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 41 ms
- Sleep
- 5.5 h
- Steps
- 8,533
- Resting HR
- 79 bpm
Daily log: GI score 55, nutritional resilience 43, adherence 70.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03382 | 49% | S01 | GI-04 | improved | 56 |
| P-03031 | 44% | S16 | CR-01 | improved | 49 |
| P-03280 | 44% | S13 | — | — | 57 |
| P-03166 | 43% | S20 | CR-01 | improved | 62 |
| P-03463 | 43% | S11 | GI-04 | no change | 55 |
| P-03191 | 42% | S19 | GI-04 | improved | 51 |
| P-03260 | 42% | S19 | — | — | 54 |
| P-03285 | 42% | S04 | — | — | 54 |
| P-03451 | 42% | S08 | — | — | 62 |
| P-03004 | 41% | S03 | — | — | 56 |
| P-03021 | 40% | S15 | — | — | 57 |
| P-03099 | 40% | S17 | CR-01 | improved | 55 |